1. Introduction {#sec1}
===============

Fetal health and development is intricately bound with human placental circulation, yet there is no validated quantitative method with which to assess vascularisation of the human placenta. Developing a quantitative method may improve our ability to investigate, and therefore understand, normal placental function and pathologies such as fetal growth restriction, stillbirth and twin-to-twin transfusion syndrome.

Micro-focus Computed Tomography (micro-CT) provides three-dimensional volume imaging with spatial resolution at the micrometre scale. The technique has been used to investigate the branching structure and tortuosity of the fetoplacental circulation of mouse placentae [@bib1] [@bib2], and shown differences in vascular density of the human placenta between normally grown and growth restricted pregnancies [@bib3], [@bib4].

This study was designed to develop optimised tissue-specific preparation and micro-CT imaging parameters, in order to provide a validated approach to human placenta micro-CT.

2. Method {#sec2}
=========

This series of experiments is divided into two sections; investigating tissue preparation techniques, and then micro-CT imaging parameters. The full experimental methodology is described in [supplementary data](#appsec1){ref-type="sec"}.

2.1. Tissue acquisition {#sec2.1}
-----------------------

Experimental procedures were approved by Bloomsbury National Research Ethics Service Committee and by University College London Hospital Research and Development (REC Reference number 133888). Placentas delivered by elective term caesarean section were taken directly to the laboratory, had the membranes trimmed, and the amnion removed.

2.2. Tissue preparation comparators {#sec2.2}
-----------------------------------

We designed experiments to compare ([Table 1](#tbl1){ref-type="table"}):•Contrast agent -- comparing Barium sulphate with Microfil (Flow Tech, Carver, MA.).•Perfusion pressure -- comparing manual pressure with no quantification of perfusion pressure, with controlled pressure of 60  mmHg, physiologically relevant to fetal life [@bib5], [@bib6], [@bib7].•Cannulation location -- comparing perfusion via the umbilical artery with perfusion via a chorionic artery.•Arterial or Venous Cannulation -- comparing perfusion via cannulation of the umbilical artery with perfusion via the umbilical vein.Table 1Comparison of placental tissue preparation and micro-CT imaging parameters used in this study and in two previous studies, and optimised protocol as determined by the results of this study. SNR = signal to noise ratio.Table 1Langheinrich [@bib4] (Human)Rennie et al.[@bib10] (Mouse)Assessment ParametersOptimised ProtocolTissue PreparationContrast AgentMicrofil and BaSO4 in gelatinMicrofilMicrofil and BaSO4 in gelatinMicrofilPerfusion Pressure (mmHg)74Not reportedManual pressure and 60No difference Manual and 60  mmHg give equivalent resultsPerfusion LocationChorionic (peripheral) perfusionUmbilical (central) PerfusionChorionic (peripheral) and umbilical (central) perfusionCentral vessel, ideally umbilical vesselPerfusion VesselChorionic plate arteryUmbilical Artery/Umbilical VeinChorionic artery/Umbilical artery/Umbilical veinArteryTissue sampling technique8 × 2 mm full thickness blocksWhole placenta8 × 2 cm full thickness blocksDependent on magnification and field of view requiredMicro CT ImagingCone-beam energy (keV)608030-100 in 10 keV increments50Target materialNot reportedNot reportedTungsten, Molybdenum, CopperMolybdenumIsotropic voxel size (μm)13 and 41313Dependent on magnification and field of view requiredRadiograph exposure time (ms)2400Not reported500/1000Balance with throughput 1000 gives good SNRNumber of projections4007203141/6282/12564Balance with throughput\
3141 gives good SNR

The fetal vessel of interest was cannulated, and a cut made in the main draining vessel close to the point of cannulation, to create a fluid exit vent. 0.9% sodium chloride solution with 5IU heparin/ml was perfused until the outflow ran clear, then contrast agent was perfused until the chorionic vasculature was fully perfused and contrast agent was seen in the draining vessel. The vessel was occluded and the contrast agent was left to set. The placenta was dissected into 2 × 2cm full thickness blocks, which were fixed in 4% formalin for a minimum of 48 h. One full thickness section stained with hematoxylin and eosin (H&E) was cut for every block and 6 micrographs at x100 magnification taken (see [supplementary material](#appsec1){ref-type="sec"}).

Histological analysis was done in FIJI (ImageJ Version 2.0.0-rc-54/1.51f) [@bib8]. Vascular fill was calculated for each micrograph as shown in equation one.$$Vascular\ Fill\ \left( \% \right) = \left( \frac{Total\ Perfused\ Vessel\ Area}{Total\ Perfused\ Vessel\ Area + Total\ Unperfused\ Vessel\ Area} \right) \times 100$$

2.3. Micro-CT imaging comparators {#sec2.3}
---------------------------------

We designed experiments to compare ([Table 1](#tbl1){ref-type="table"}).•Energy level -- from 30 to 100 keV in 10 keV increments.•Target material -- comparing Tungsten, Copper and Molybdenum.•Exposure time--500 and 1000 ms•Averaged frames per projection--1 and 2

A 2 × 2cm full thickness block of human placenta was repeatedly imaged (XT H 225 ST Micro-CT, Nikon Metrology, Tring, UK) adjacent to a 3 mm internal diameter tube filled with Microfil. Scans were reconstructed using a modified Feldkamp filtered back projection algorithm with proprietary software (CTPro3D; Nikon Meterology), and the average greyscale values of recorded areas of interest drawn over placenta, Microfil and air were calculated. The contrast to noise ratio was calculated as shown in equation two.$$Contrast\ to\ Noise\ ratio\ \left( {CNR} \right) = \ \frac{\left( {Placenta\ Grey\ Scale\ Value - Microfil\ Grey\ Scale\ Value} \right)}{Standard\ Deviation\ of\ Signal\ of\ Air}$$

2.4. Statistical analysis {#sec2.4}
-------------------------

Data is presented as mean ± SD. Statistical analysis was done in SPSS Statistics (IBM version 23). Group comparison was performed using independent sample t-tests with significance set at 95%.

3. Results {#sec3}
==========

3.1. Tissue preparation comparators {#sec3.1}
-----------------------------------

There was lower mean vascular fill with barium sulphate than Microfil (70.4% (±18.02%) BaSo4 vs 84.1% (±11.5%) Microfil, (p = 0.01)) and barium sulphate was seen in the extravascular space in all three blocks sampled (47% of micrographs), whereas Microfil was never seen in the extravascular space.

There was no significant difference in vascular fill between manual or controlled 60  mmHg perfusion pressure (77.8%(±13.9%) manual vs 78.0%(±21.9%) controlled pressure p = 0.95). Perfusion via an umbilical artery achieved higher vascular fill than perfusion via a more peripheral chorionic vessel (83.8%(±17.7%) umbilical artery vs 78.0%(±21.9%) chorionic artery, p \< 0.05). Umbilical arterial perfusion produced higher vascular fill than umbilical venous perfusion (83.8%(±16.4%) umbilical artery vs 69.8%(±20.3%) umbilical vein p \< 0.01) (see [Table 1](#tbl1){ref-type="table"} for summary, and supplementary data [Table 1](#appsec1){ref-type="sec"} for full results).

3.2. Micro-CT imaging parameters {#sec3.2}
--------------------------------

Contrast and noise were both greatest at the lower energy levels ([Fig. 1](#fig1){ref-type="fig"}A/B). The optimal CNR was with Molybdenum target at 50 keV ([Fig. 1](#fig1){ref-type="fig"}C). Increasing exposure time from 500 ms to 1000 ms and averaged frames per projection reduced the noise and improved the CNR ([Fig. 1](#fig1){ref-type="fig"}D) at the cost of imaging time and throughput ([Table 1](#tbl1){ref-type="table"}).Fig. 1Identifying optimal micro-CT imaging parameters for Contrast to Noise Ratio (CNR). **A:** Contrast (defined as Microfil Grey Scale value -- placental issue Grey Scale value, arbitrary units) between placenta and Microfil grey scale value with increasing energy for Molybdenum, Tungsten and Copper target. **B:** Standard deviation of the signal in air, the image noise, with increasing energy for Molybdenum, Tungsten and Copper target. **C:** Contrast to noise ratio with increasing energy for Molybdenum, Tungsten and Copper target. **D:** Effect of increasing the exposure time and the averaged frames per projection on the CNR.Fig. 1

4. Discussion {#sec4}
=============

We have established optimal tissue and imaging parameters for placental angiographic micro-CT ([Table 1](#tbl1){ref-type="table"}). Our studies show that Microfil is a superior contrast agent to barium suphate, and that central and arterial perfusion are superior to peritheral and venous perfusion. Contrast to noise ratio is optimal when imaging with 50 keV energy, with a Molybdenum target. Increasing the number of projection and exposure time improves CNR at the cost of throughput. Our studies found 1000 ms exposure time and 3141 projections over 360° rotation produced good CNR with a 54 min scan time.

This approach can be used to investigate the microcirculation of the human placenta. The technique benefits from its high resolution and large field of view, allowing images of the vascular tree to be captured from the chorionic plate to the intermediate villous vessels (see [supplementary data](#appsec1){ref-type="sec"} for images).

Micro-CT allows measurement of vascular density and analysis of the structure of the vascular trees, which could improve our understanding of the heterogeneity within normal placentae, and the structural changes associated with diseases such as early and late intrauterine growth restriction.
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